Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Guo, Zhiqiang ^a   Cheng, Dali ^a   Xia, Zhijun ^a   Luan, Meng ^a   Wu, Liangliang ^b   Wang, Gang ^b   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIBODY; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 4; MONOCLONAL ANTIBODY; STAT6 PROTEIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 ANTIBODY; TRANSCRIPTION FACTOR GATA 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD4+FOXP3+ REGULATORY T CELL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MOUSE; MYELOID SUPPRESSOR CELL; NONHUMAN; OVARY CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TH1 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; PERITONEAL LAVAGE; RECEPTORS, VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84883853182     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-215     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Leary A, Pautier P, Tazi Y, Morice P, Duvillard P, Gouy S, Uzan C, Gauthier H, Balleyguier C, Lhomme C. The molecular biology of epithelial ovarian cancer. Bulletin du cancer 2012, 99(12):1161-1173.
3. Wei H, Hellstrom KE, Hellstrom I. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 2012, 125(3):727-733. 10.1016/j.ygyno.2012.03.018, 3358520, 22430613.
4. Kandalaft LE, Powell DJ, Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next?. J Clin Oncol 2011, 29(7):925-933. 10.1200/JCO.2009.27.2369, 3068064, 21079136.
5. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003, 15(6):751-763. 10.1093/intimm/dxg074, 12750359.
6. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001, 51(4):254-261. 10.1159/000058060, 11408737.
7. Schondorf T, Engel H, Kurbacher CM, Brenne U, Kolhagen H, Gohring UJ, Scharl A, Mallmann P. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. J Soc Gynecol Investig 1998, 5(2):102-107. 10.1016/S1071-5576(97)00112-3, 9509389.
8. Wei H, Liu P, Swisher E, Yip YY, Tse JH, Agnew K, Hellstrom KE, Hellstrom I. Silencing of the TGF-beta1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother 2012, 35(3):267-275. 10.1097/CJI.0b013e31824d72ee, 3327124, 22421944.
9. Vermeij R, Leffers N, Melief CJ, Daemen T, Nijman HW. Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 2012, 18(25):3804-3811. 10.2174/138161212802002805, 22591425.
10. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348(3):203-213. 10.1056/NEJMoa020177, 12529460.
11. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009, 119(8):2231-2244. 2719935, 19620771.
12. Mantia-Smaldone GM, Corr B, Chu CS. Immunotherapy in ovarian cancer. Hum Vaccin Immunother 2012, 8(9):1179-1191. 10.4161/hv.20738, 3579897, 22906947.
13. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010, 235(1):172-189. 2914464, 20536563.
14. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415(6871):536-541. 10.1038/415536a, 11823861.
15. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318(5853):1141-1143. 10.1126/science.1148536, 18006747.
16. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011, 71(21):6567-6571. 10.1158/0008-5472.CAN-11-1487, 22009533.
17. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol 2002, 169(10):5912-5918.
18. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011, 32(8):345-349. 10.1016/j.it.2011.05.003, 3164311, 21697013.
19. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6(12):1245-1252. 10.1038/ni1271, 16286920.
20. Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, Nishi N, Yamauchi A, Quintana FJ, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b + Ly-6G + myeloid cells. J Immunol 2010, 185(3):1383-1392. 10.4049/jimmunol.0903275, 2925247, 20574007.
21. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009, 229(1):192-215. 10.1111/j.1600-065X.2009.00765.x, 19426223.
22. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997, 186(1):47-55. 10.1084/jem.186.1.47, 2198949, 9206996.
23. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3(6):682-685. 10.1038/nm0697-682, 9176498.
24. Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, Hewes LB. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res 2004, 29(1-3):197-208.
25. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 2008, 118(1):376-386. 10.1172/JCI33365, 2104483, 18060045.
26. Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, Lieber A, Hellstrom I, Hellstrom KE. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res 2007, 67(5):2339-2344. 10.1158/0008-5472.CAN-06-3593, 17332366.
27. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010, 37(5):508-516. 10.1053/j.seminoncol.2010.09.008, 21074066.
28. Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 2013, 36(4):248-257. 10.1097/CJI.0b013e3182943549, 23603859.
29. Chang CL, Wu TC, Hung CF. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther 2007, 14(16):1189-1198. 10.1038/sj.gt.3302974, 3182456, 17581599.
30. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002, 109(5):651-659. 150893, 11877473.
31. Johnston FM, Tan MC, Tan BR, Porembka MR, Brunt EM, Linehan DC, Simon PO, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009, 15(21):6511-6518. 10.1158/1078-0432.CCR-09-0565, 2782601, 19843662.
32. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005, 11(10):3814-3820. 10.1158/1078-0432.CCR-04-2304, 15897581.
33. Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 2009, 8(2):469-478. 10.1158/1535-7163.MCT-08-0993, 19190115.
34. Kim J, Kim W, Kim HJ, Park S, Kim HA, Jung D, Choi HJ, Park SJ, Mittler RS, Cho HR, et al. Host CD25 + CD4 + Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18(1):44-54. 10.1016/j.bbmt.2011.09.004, 21958951.
35. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011, 71(10):3540-3551. 10.1158/0008-5472.CAN-11-0096, 21430066.
36. Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother 2013, 62(4):629-637. 10.1007/s00262-012-1371-9, 23143694.
37. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465. 10.1056/NEJMoa1200694, 3563263, 22658128.
38. Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog 2013, 9(3):e1003253. 10.1371/journal.ppat.1003253, 3605152, 23555261.
39. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007, 178(7):4194-4213. 2770095, 17371976.
40. Dubrot J, Milheiro F, Alfaro C, Palazon A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervas-Stubbs S, et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother 2010, 59(8):1223-1233. 10.1007/s00262-010-0846-9, 20336294.
41. Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Penuelas I, Hervas-Stubbs S, Rouzaut A, et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Canc Discov 2012, 2(7):608-623.
42. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012, 72(13):3163-3174. 10.1158/0008-5472.CAN-12-0210, 22570253.
43. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013, 12(2):130-146. 10.1038/nrd3877, 23370250.